PMID- 21941284
OWN - NLM
STAT- MEDLINE
DCOM- 20111201
LR  - 20220410
IS  - 1474-1768 (Electronic)
IS  - 1474-175X (Print)
IS  - 1474-175X (Linking)
VI  - 11
IP  - 10
DP  - 2011 Sep 23
TI  - A decade of exploring the cancer epigenome - biological and translational 
      implications.
PG  - 726-34
LID - 10.1038/nrc3130 [doi]
AB  - The past decade has highlighted the central role of epigenetic processes in 
      cancer causation, progression and treatment. Next-generation sequencing is 
      providing a window for visualizing the human epigenome and how it is altered in 
      cancer. This view provides many surprises, including linking epigenetic 
      abnormalities to mutations in genes that control DNA methylation, the packaging 
      and the function of DNA in chromatin, and metabolism. Epigenetic alterations are 
      leading candidates for the development of specific markers for cancer detection, 
      diagnosis and prognosis. The enzymatic processes that control the epigenome 
      present new opportunities for deriving therapeutic strategies designed to reverse 
      transcriptional abnormalities that are inherent to the cancer epigenome.
FAU - Baylin, Stephen B
AU  - Baylin SB
AD  - The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, 
      Maryland 21231, USA. sbaylin@jhmi.edu
FAU - Jones, Peter A
AU  - Jones PA
LA  - eng
GR  - R01 CA043318/CA/NCI NIH HHS/United States
GR  - R37 CA082422/CA/NCI NIH HHS/United States
GR  - R37 CA082422-14/CA/NCI NIH HHS/United States
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110923
PL  - England
TA  - Nat Rev Cancer
JT  - Nature reviews. Cancer
JID - 101124168
SB  - IM
MH  - Animals
MH  - *Epigenesis, Genetic
MH  - Epigenomics/*history
MH  - Genome
MH  - History, 20th Century
MH  - History, 21st Century
MH  - Humans
MH  - Neoplasms/drug therapy/*genetics/*history/metabolism
MH  - *Translational Research, Biomedical/history
PMC - PMC3307543
MID - NIHMS358721
COIS- Competing interests statement The authors declare competing financial interests. 
      See Web version for details.
EDAT- 2011/09/24 06:00
MHDA- 2011/12/13 00:00
PMCR- 2012/03/19
CRDT- 2011/09/24 06:00
PHST- 2011/09/24 06:00 [entrez]
PHST- 2011/09/24 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2012/03/19 00:00 [pmc-release]
AID - nrc3130 [pii]
AID - 10.1038/nrc3130 [doi]
PST - epublish
SO  - Nat Rev Cancer. 2011 Sep 23;11(10):726-34. doi: 10.1038/nrc3130.